Tandem Diabetes Care Announces Retirement of CFO and Successor Appointment
December 07 2017 - 4:30PM
Business Wire
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the
retirement of its executive vice president and chief financial
officer (CFO), John Cajigas, effective December 31, 2017. Leigh
Vosseller, who is currently serving at Tandem’s senior vice
president of finance, will be promoted to CFO effective January 1,
2018.
“I want to thank John for his many contributions to Tandem over
the past 10 years and wish him the best of luck in his future
endeavors,” said Kim Blickenstaff, president and chief executive
officer of Tandem Diabetes Care. “Leigh brings a passion for
leading teams, delivering results, and providing financial
stewardship and discipline that makes her ideally suited for this
expanded role. With our positive sales momentum in the fourth
quarter, and our anticipation of key business inflection points in
2018, we expect Leigh will play a pivotal role as we drive toward
sustained profitable growth.”
Ms. Vosseller joined Tandem in September 2013 as vice president
of finance. Prior to that time, she served as vice president and
CFO at Genoptix, Inc. (a Novartis company) beginning in 2011, after
initially joining the company in 2008. Prior to that she held a
senior finance position at Biosite Incorporated where she played a
key role in developing the financial and administrative
infrastructure for international expansion. Ms. Vosseller is a
certified public accountant (inactive) and holds a bachelor’s
degree in accounting from Missouri State University.
Mr. Cajigas’ retirement is not related to any disagreement with,
or inaccuracy or omission in, the Company's accounting systems or
financial reporting.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach
to the design, development and commercialization of products for
people with diabetes who use insulin. Tandem manufactures and sells
the t:slim X2™ Insulin Pump, the only pump capable of remote
feature updates using a personal computer, and the t:flex® Insulin
Pump, the first pump designed for people with greater insulin
requirements. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2, #tflex, #tconnect, and $TNDM.Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.Follow Tandem
Diabetes Care on LinkedIn at
https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care and t:flex are registered trademarks, and
t:slim X2 and t:simulator are trademarks of Tandem Diabetes Care,
Inc. Dexcom and Dexcom G5 are registered trademarks of Dexcom, Inc.
All other trademarks are the property of their respective
owners.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. These forward-looking statements include
statements regarding the Company’s sales momentum and future
profitability. The Company's actual results may differ materially
from those indicated in these forward-looking statements due to
numerous risks and uncertainties. For instance, the Company’s
ability to achieve future profitability will be impacted by market
acceptance of the Company’s new products and products under
development by healthcare providers, third-party payors and people
with diabetes; the potential that negative perceptions regarding
the Company’s financial stability relative to that of its
competitors, and its ability to sustain business operations on a
long-term basis, may cause consumers to delay the purchase of its
products or to purchase competitive products; the Company’s ability
to receive required regulatory approvals and otherwise complete the
transition of manufacturing operations to its new manufacturing
facility when anticipated; and the potential that newer products
that compete with the Company’s products, or other technological
breakthroughs for the monitoring, treatment or prevention of
diabetes, may render its products obsolete or less desirable. Other
risks and uncertainties are identified in the Company’s most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and
other documents that the Company files with the Securities and
Exchange Commission. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to
update or review any forward-looking statement in this press
release because of new information, future events or other
factors.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171207006143/en/
Tandem Diabetes Care, Inc.Media Contact:Steve Sabicer,
714-907-6264ssabicer@thesabicergroup.comorInvestor
Contact:Susan Morrison, 858-366-6900
x7005smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2023 to Apr 2024